Please assess the completion status of the following clinical trial:

Trial Title: A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Each subject must meet the following criteria:~  1. Provide signed, written informed consent prior to the initiation of any study-specific procedures (Consent from Guardians for minor children and patient assent according to Institution and Institutional Review Board (IRB) standards)~ 2. Are male or female aged ≥ 1 to 30 years~ 3. Have histologically or cytologically confirmed relapsed solid tumor cancer, including recurrent malignant brain tumors, for which there is no further standard therapy or when standard therapy is contraindicated • Recurrent malignant brain tumors: must have shown unequivocal evidence for recurrence or progression by MRI scan or must have histologically proven tumor recurrence • Recurrent malignant brain tumors: must have previously received standard of care treatment at initial diagnosis (radiation and/or chemotherapy)~     * Recurrent malignant brain tumors receiving glucocorticoid therapy: must be on stable or decreasing equivalent daily dose of glucocorticoids for 2 weeks (14 days) prior to dose assignment~    * Recurrent embryonal tumors or atypical teratoid rhabdoid tumors (AT/RT): must have previously received standard of care therapy including either chemotherapy and radiation therapy or high dose chemotherapy with autologous hematopoietic stem cell support~    * Grade II or III recurrent ependymoma, including RELA fusion-positive ependymoma: must have previously received radiation therapy~ 4. Have measurable or non-measurable disease per RECIST v1.1 for relapsed solid tumors, RRC for recurrent malignant brain tumors, and INRC for recurrent neuroblastomas~ 5. Have Lansky (age 1 - 15) / Karnofsky (age ≥ 16) Performance Score of \>50 or Eastern Cooperative Oncology Group Performance Status (ECOG PS) (age ≥ 18) of 0 - 2~ 6. Have acceptable liver function defined as:~     * Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN) for the study site (in subjects with known Gilbert Syndrome, total bilirubin ≤ 3 × ULN, with direct bilirubin ≤ 1.5 × ULN)~    * Aspartate Transaminase (AST), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alanine Transaminase (ALT), Serum Glutamic-Pyruvic Transamine (SGPT) ≤ 3 × ULN (if liver metastases are present, then ≤ 5 × ULN is allowed)~    * Serum albumin ≥ 3 g/dL~ 7. Have acceptable renal function defined as:~     * Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥70 mL/min/1.73m² or a maximum serum creatinine (mg/dL)\* based on age/gender as follows:~       1 to \< 2 years: 0.6 (male); 0.6 (female)~       2 to \< 6 years: 0.8 (male); 0.8 (female)~       6 to \< 10 years: 1 (male); 1 (female)~       10 to \< 13 years: 1.2 (male); 1.2 (female)~       13 to \< 16 years: 1.5 (male); 1.4 (female)~       ≥ 16 years: 1.7 (male); 1.4 (female)~       \* Threshold creatinine values derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the CDC (Schwartz 2009)~ 8. Have acceptable bone marrow function defined as:~     * Absolute neutrophil count (ANC) ≥ 750 cells/mm3~    * Platelet count ≥ 75,000 cells/mm3~    * Hemoglobin \> 9.0 g/dL~ 9. Have acceptable coagulation parameters defined as:~     * International normalized ratio (INR) ≤ 2 × ULN~    * Activated partial thromboplastin time (aPTT) within normal limits~    * Chronic/prophylactic anticoagulation for a distant thrombus that occurred ≥3 months ago is allowed~ 10. Have a negative serum pregnancy test result at screening (for females of child bearing potential (FCBP); not applicable to subjects who are unable to become pregnant, including those with tubal ligation, bilateral oophorectomy and/or hysterectomy)~ 11. FCBP and male subjects whose sexual partner(s) are FCBP must agree to abstain from heterosexual activity or use a double barrier method of contraception (e.g., condom and occlusive cap with spermicide) or highly effective contraception (intrauterine device or system, established hormonal contraceptive methods on a stable dose from the time of the last menstrual cycle, or vasectomized partner with confirmed azoospermia) from the time of study entry to 1 month after the last day of treatment~Exclusion Criteria:~- Subjects must not meet any of the following criteria:~1. Have a concurrent or second malignancy~2. Have lymphoma~3. Have Grade I ependymoma~4. Relapsed solid tumors: have symptomatic brain metastases or leptomeningeal disease~5. Relapsed solid tumors: have received~   * anticancer therapies within 2 weeks prior to dose assignment (including radiation therapy, cytotoxic agents, targeted agents or endocrine therapy)~  * myelosuppressive agents within 3 weeks prior to dose assignment~  * monoclonal antibodies within 4 weeks prior to dose assignment~  * growth factors within 2 weeks of dose assignment~  * other immunotherapy (tumor vaccine, cytokines) within 4 weeks of dose assignment~6. Recurrent malignant brain tumors: have received~   * anticancer therapies including: radiation therapy to current site of disease within 3 weeks dose assignment; targeted agent therapy within 2 weeks of dose assignment; nitrosoureas within 6 weeks of dose assignment; procarbazine within 3 weeks of dose assignment; other cytotoxic agents withing 4 weeks of dose assignment~  * myelosuppressive agents within 4 weeks prior to dose assignment~  * monoclonal antibodies within 4 weeks prior to dose assignment~  * other immunotherapy (tumor vaccine, cytokines, or growth factor) within 2 weeks prior to dose assignment~7. Have not recovered from toxicity of prior therapy defined as a return to ≤ grade 1 at the time of dose assignment, graded according to CTCAE v5.0 (excluding alopecia, neuropathy, and lymphopenia)~8. Have had major surgery other than a minor outpatient procedure within 28 days prior to dose assignment or have not recovered from major side effects of the surgery if more than 4 weeks have elapsed since surgery~9. Have poorly controlled hypertension despite the use of antihypertensive agents defined as blood pressure ≥95th percentile for age and weight or \>160/90 on at least 2 repeated determinations on separate days within 2 weeks (14 days) prior to initiation of screening~10. Have a history of cardiac dysfunction including any of the following:~    * Myocardial infarction within 6 months prior to initiation of screening~   * History of documented congestive heart failure (New York Heart Association functional classification III-IV, see Appendix 6) within 6 months prior to initiation of screening~   * Active cardiomyopathy~   * Electrocardiogram (ECG) with QTc \>480 msec at screening~   * Echocardiogram with ejection fraction \<50% or a decrease in the left ventricular shortening fraction to \<27%~11. Have a known history of Human Immunodeficiency Virus (HIV) seropositivity~12. Have active (acute or chronic) or uncontrolled severe infections~13. Have active poor wound healing (delayed healing, wound infection or fistula)~14. Have evidence of active clinically significant bleed (e.g., gastrointestinal bleed, hemoptysis, or gross hematuria) at initiation of screening~15. Are pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test~16. Have received prior treatment with any investigational drug within 28 days prior to dose assignment~17. Have other concurrent severe and/or uncontrolled medical condition that would, in the site Investigator's judgment contraindicate the subject's participation in the clinical study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 Dose Escalation: Safety and Tolerance (Type: EXPERIMENTAL): Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
- Part 2: Ependymoma Patients (Type: EXPERIMENTAL): Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
- Part 2: Brain Tumor Patients (Type: EXPERIMENTAL): Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
- Part 2: DIPG Patients (Type: EXPERIMENTAL): Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
- Part 2: Other Solid Tumor Patients (Type: EXPERIMENTAL): Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy